Previously treated metastatic HER2+Breast Cancer
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)
New sub-study includes margetuximab plus chemotherapy with decreased infusion time.
Study Record Detail
For a list of our open studies click here.
Our Research Staff:
Principal Investigators Mikhail Shtivelband, MD, Ph.D. and Sujith Kalmadi, MD, oversee sub-investigators participating in trials that involve Ironwood Women’s Centers and Ironwood Cancer & Research Centers. If you are interested in contacting one of our research staff members, please click here.
For a list of our closed studies click here.